Shukra Pharmaceuticals Limited specializes in Pharmaceuticals within the Healthcare sector.
Shukra Pharmaceuticals Limited, with Security Code 524632, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
---|---|---|---|---|---|---|---|---|---|
2024-01-01 | 2024-03-31 | 108.84 | 39.86 | 122.61 | 3.64 | - | 13.77 | -5.17 | 52.24 |
2023-10-01 | 2023-12-31 | 188.91 | 94.22 | 194.53 | 8.61 | -7.20 | 5.62 | -5.12 | 95.29 |
2023-07-01 | 2023-09-30 | 246.38 | 47.09 | 248.81 | 1.47 | -5.02 | 2.43 | -5.62 | 47.04 |
2023-04-01 | 2023-06-30 | 201.60 | 4.20 | 207.94 | 0.59 | -5.68 | 6.34 | -4.59 | 4.27 |
Compounded Sales Growth | |
---|---|
10 Years: | 33% |
5 Years: | 67% |
3 Years: | 88% |
TTM: | 27% |
Compounded Profit Growth | |
---|---|
10 Years: | 39% |
5 Years: | 109% |
3 Years: | 410% |
TTM: | 320% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 108% |
3 Years: | 225% |
1 Year: | 134% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | 0% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
1 Year: | 0% |
The drug, called Shukramycin, is a broad-spectrum antibiotic that is effective against a wide range of bacteria, including those that are resistant to other antibiotics.
The company reported a 15% increase in revenue and a 20% increase in net income for the fiscal year ended March 31, 2023.
The partnership will allow Shukra Pharmaceuticals to expand its reach into new markets and to develop new products.
The company is investing in new manufacturing facilities and expanding its sales force to meet growing demand for its products.